Document:

Second Amendment to Exhibit A-5

 Exhibit 10.2 
 Confidential 
 Second Amendment to Exhibit A-5 to Master
Services Agreement 
 THE UNDERSIGNED HEREBY ACKNOWLEDGE AND AGREE THAT THIS SECOND AMENDMENT TO EXHIBIT A-5 IS INCORPORATED BY REFERENCE INTO, AND
SUBJECT TO THE PROVISIONS OF THAT CERTAIN MASTER SERVICES AGREEMENT BETWEEN THE PARTIES DATED MAY 24, 2007, AS AMENDED (THE “AGREEMENT”). 
  

	 	1.	This Second Amendment to Exhibit A-5 to Master Services Agreement and the Scope of Works and Budgets attached hereto as Appendix 1 (the “Set-Up Plan”) , and the
Scope of Work and Budget attached hereto as Appendix 2 (the “Safety Plan”) (collectively, this “Second Amended Exhibit A-5”) sets forth the agreed to Services, fees, pass through costs and related compensation for Raifarm Limited
relating to commercialization set-up activities in Russia for Oncophage from April 1, 2008, and the pharmacovigilance and associated regulatory support for Oncophage in Russia. This Second Amended Exhibit A-5 hereby replaces the provisions of
the Amendment to Exhibit A-5 to Master Services Agreement entered into by the Parties on June 5, 2008 (“First Amended Exhibit A-5”). Capitalized terms not otherwise defined shall have the meaning set forth in the Agreement.

  

	 	2.	The Parties acknowledge that work for some of the tasks under Appendix 1 has already commenced, and some hours set forth in the Appendix 1 have already been utilized in performance
of the tasks. The Parties further acknowledge and agree that Company shall only be responsible to provide compensation to Raifarm Limited for hours actually utilized in performance of the Services, such hours and compensation not to exceed the
amounts set forth in Appendix 1 and Appendix 2 without the prior written consent of Company. 

  

	 	3.	The Parties acknowledge that the provisions of Paragraph 3 of the First Amended Exhibit A-5 is deleted in its entirety, and that the provisions of Paragraph 2 and 4 of the First
Amended Exhibit A-5 remain in full force and effect, provided however, that any payments to Raifarm after the Effective Date of this Second Amended Exhibit A-5 shall be payable by the Company in the form of U.S. dollars cash.

 Acknowledged and Agreed: 
  

							
	ANTIGENICS Inc., a Delaware corporation	  	RAIFARM LIMITED
				
	By:	 	 /s/ Garo Armen
	  	By:	 	 /s/ Yuri Raifeld

				
	Date:	 	 1/14/09
	  	Date:	 	 December 17, 2008

				
	Typed Name:	 	 Garo Armen
	  	Typed Name:	 	 Yuri Raifeld

				
	Title:	 	 Chairman & CEO
	  	Title:	 	 Director

 Appendix 1 
 [See attached Appendix 1 Set Up Plan] 

 Exhibit 10.2 
 Confidential 
  

 Appendix 1 
 [see
attached] 

 Exhibit 10.2 
 Confidential 
  

 Set-Up Plan [**] 
 [**]

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission. 

 Exhibit 10.2 
 Confidential 
  

 Appendix 2 
 [**]

  
 [**] = Portions of this agreement have
been omitted pursuant to a confidential treatment request. An unredacted version of this agreement has been filed separately with the Commission.Amendment of Rights

 Exhibit 10.4 
 ANTIGENICS, INC. 
 Amendment of Rights with respect to Events of Default and Issuance of Other
Securities 
 RECITALS 
 WHEREAS, reference is made to the Senior Secured Convertible Notes issued on October 30, 2006 (together with any senior secured convertible notes issued in replacement or exchange thereof in accordance with the terms thereof and any
senior secured convertible notes issued to pay interest, the “2006 Notes” and each a “2006 Note”), by Antigenics, Inc., a Delaware corporation (the “Company”) to Ingalls & Snyder Value
Partners L.P. (“Ingalls”) and Penrith LTD (“Penrith”, and together with Ingalls, the “Investors”); 
 WHEREAS, pursuant to the Indenture, dated January 25, 2005, between the Company and HSBC Bank USA, National Association, the Company issued $50.0 million of 5.25% Convertible Senior Notes due 2025 (the
“2005 Notes”) in a private placement; 
 WHEREAS, the Company desires, at any time and from time to time, to redeem and
repurchase up to $15,000,000 in aggregate principal amount of 2005 Notes, along with accrued but unpaid interest, for cash, from certain holders thereof (the “2005 Notes Redemption”); 
 WHEREAS, pursuant to Section 4(a)(ii) of the 2006 Notes, the 2005 Notes Redemption will constitute an Event of Default (as defined in the 2006
Notes); 
 WHEREAS, pursuant to Section 4(b) of the 2006 Notes, the Investors will have certain redemption rights upon the occurrence of
the Event of Default that results from the 2005 Notes Redemption (the “Event of Default Rights”); 
 WHEREAS, at any time
and from time to time, the Company may issue and sell shares of Company Common Stock (as defined in the 2006 Notes), Convertible Securities (as defined in the 2006 Notes), Options (as defined in the 2006 Notes) or any combination thereof
(collectively, the “New Securities”) through a public offering or a private placement (each a “Replenishment Offering”); 
 WHEREAS, pursuant to Section 7(a) of the 2006 Notes, the Investors may have certain anti-dilutive rights upon the Company’s issuance and sale of New Securities through a Replenishment Offering (the
“Anti-Dilutive Rights”) if the Replenishment Offering constitutes a Dilutive Issuance (as defined in the 2006 Notes); 
 WHEREAS, the undersigned parties desire to permit the 2005 Notes Redemption subject to the terms and conditions set forth herein without triggering the Event of Default Rights; 
 WHEREAS, the undersigned parties desire to permit each Replenishment Offering subject to the terms and conditions set forth herein without triggering the
Anti-Dilutive Rights; 
 WHEREAS, pursuant to Section 15 of the 2006 Notes, the terms of the 2006 Notes may be changed or amended by
either (i) the affirmative vote at a meeting duly called for such purpose or (ii) the written consent without a meeting, of the holders of 2006 Notes representing at least a majority of the aggregate principal amount of the 2006 Notes then
outstanding; and 

 WHEREAS, Ingalls holds 2006 Notes representing 80% of the aggregate principal amount of the 2006 Notes
outstanding; 
 NOW, THEREFORE, in consideration of the promises and agreements set forth in this Amendment of Rights with respect to Events
of Default and Issuance of Other Securities (this “Amendment”), the undersigned agree as follows: 
 AGREEMENT

  

	1.	Definitions.    Capitalized terms used in this Amendment without definition shall have the meanings ascribed to them in the 2006 Notes.

  

	2.	Amendment. 

  

	 	a.	The parties hereto hereby amend the Event of Default Rights by excluding the 2005 Note Redemption from the definition of an Event of Default in Section 4(a)(ii) of the 2006
Notes, subject to the condition that, in connection with the 2005 Note Redemption, redemptions or repurchases by the Company of 2005 Notes be at a purchase price that does not exceed the sum of (i) twenty-five percent (25%) of the
outstanding principal of such notes plus (ii) the accrued but unpaid interest on such notes. 

  

	 	b.	The parties hereto hereby amend Section 7(a) of the 2006 Notes by excluding each Replenishment Offering from the definition of a Dilutive Issuance, subject to the following
conditions: 

  

	 	i.	If the New Issuance Price for such Replenishment Offering is less than $1.00 per share, then (a) immediately after such Replenishment Offering, the Fixed Conversion Price then
in effect shall be reduced in the amount of the difference between $1.00 per share and the New Issuance Price, and (b) for purposes of determining the adjusted Fixed Conversion Price, Section 7(a)(i)-(iv) of the 2006 Notes shall apply
and “Applicable Price” shall mean $1.00 per share with respect to such Replenishment Offering. 

  

	 	ii.	This section 2.b shall apply to up to an aggregate number of shares of Company Common Stock (a) issued and sold through all Replenishment Offerings and (b) available for
issuance under Options and/or Convertible Securities sold through all Replenishment Offerings, equal to ten percent (10%) of the total number of shares of Company Common Stock issued and outstanding on the Business Day immediately preceding the
consummation of the Replenishment Offering in question. 

  

	 	iii.	The aggregate dollar amount raised in the Replenishment Offerings is not to exceed the aggregate dollar amount (excluding accrued but unpaid interest) expended by the Company on any
2005 Note Redemptions. 

  

 -2- 

	3.	Miscellaneous.    Other than as specifically set forth herein, this Amendment shall not be construed as a consent to any future action or an amendment of
any right or remedy on any future occasion. This Amendment may be executed in one or more counterparts, all of which shall be considered one and the same amendment. 

 [Signature Page Follows] 
  

 -3- 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of November
    11    , 2008. 
  

			
	ANTIGENICS, INC.
		
	By:	 	/s/    Garo H. Armen
	Name:	 	Garo H. Armen, Ph.D.
	Title:	 	Chairman & CEO
	
	INGALLS & SNYDER VALUE PARTNERS L.P.
		
	By:	 	/s/    Thomas O. Boucher
	Name:	 	Thomas O. Boucher
	Title:	 	General PartnerAmendment to Employee Agreement - William Conner

 EXHIBIT 10.1 
 ENTRUST, INC. 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This amendment (the “Amendment”) is made by and between William Conner (the “Executive”) and Entrust, Inc., a Maryland corporation
(the “Company” and together with the Executive hereinafter collectively referred to as the “Parties”) on December 31, 2008. 
 WITNESSETH: 
 WHEREAS, the Parties previously entered into an employment agreement, dated
April 22, 2001 (the “Agreement”); and 
 WHEREAS, the Parties wish to amend the Agreement, and bring certain terms
into documentary compliance with Section 409A of the Internal Revenue Code and the final regulations and other official guidance thereunder (“Section 409A”) so as to avoid the imposition of any additional tax under Section 409A,
as set forth below. 
 NOW, THEREFORE, for good and valuable consideration, Executive and the Company agree that the Agreement is
hereby amended as follows: 
 1. Bonus. Section 2(b) of the Agreement is hereby amended to add the following new sentence to the
end thereof: 
 “Any annual bonus under this Section 2(b) shall be paid no
later than the March 15th of the year following the year in which such annual bonus was earned.” 
 2. Code Section 409A. A new Section 11 is hereby inserted into the Agreement to provide as follows: 
 “11. Code Section 409A. 
 (a) Reimbursement. To the extent that any taxable reimbursements of expenses or in-kind benefits are provided under this Agreement, they shall be made in accordance with
Section 409A, including, but not limited to the following provisions: 
  

	 	i)	The amount of any such expense reimbursement or in-kind benefit provided during any one of Executive’s taxable years shall not affect any expenses eligible for reimbursement in
any other taxable year; 

  

	 	ii)	The reimbursement of the eligible expense shall be made no later than the last day of the Executive’s taxable year that immediately follows the taxable year in which the
expense was incurred; and 

	 	iii)	The right to any reimbursement shall not be subject to liquidation or exchange for another benefit or payment. 

 (b) Deferred Payments. Notwithstanding anything to the contrary in this Agreement, no Deferred Payments (as defined below) shall be payable until
Executive has a “separation from service” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the final regulations and official guidance thereunder (together, “Section
409A”). Similarly, no severance payable to Executive, if any, pursuant to this Agreement that would otherwise be exempt from Section 409A pursuant to Treasury Regulation 1.409A-1(b)(9) shall be payable until Executive has a
“separation from service” within the meaning of Section 409A. 
 (c) Timing of Deferred Payments. Further, if
Executive is a “specified employee” within the meaning of Section 409A at the time of Executive’s separation from service (other than due to death), and the severance payments and benefits payable to Executive, if any, pursuant
to the Agreement, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, the “Deferred Payments”), such Deferred Payments that are
otherwise payable within the first 6 months following Executive’s separation from service will become payable on the first payroll date that occurs on or after the date 6 months and 1 day following the date of Executive’s separation from
service. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s
separation from service but prior to the 6 month anniversary of Executive’s separation from service (or any later delay date), then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively
practicable after the date of Executive’s death and all other Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under the Agreement is intended to
constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (d) Construction of
Section 11. The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided under the Agreement will be subject to the additional tax imposed
under Section 409A, and any ambiguities herein will be interpreted to so comply. Executive and the Company agree to work together in good faith to consider amendments to the Agreement and to take such reasonable actions which are necessary,
appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to Executive under Section 409A.” 
 3. Full Force and Effect. To the extent not expressly amended hereby, the Agreement shall remain in full force and effect. 
 4. Entire Agreement. This Amendment and the Agreement constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof. 

 5. Successors and Assigns. This Amendment and the rights and obligations of the parties hereunder
shall inure to the benefit of, and be binding upon, their respective successors, assigns, and legal representatives. 
 6. Governing
Law. This Amendment will be governed by the laws of the State of Texas (with the exception of its conflict of laws provisions). 
 [signature page to follow] 

 IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company by
its duly authorized officer, as of the day and year set forth above. 
  

							
	COMPANY	 		 	ENTRUST, INC.
				
		 		 	By:	 	 /s/ Jay D. Kendry

		 		 	Title:	 	 VP & CGO

		 		 	Date:	 	 Dec. 31, 2008

				
	EXECUTIVE	 		 	By:	 	 /s/ F. William Conner

		 		 	Title:	 	 President & CEO

		 		 	Date:	 	 Dec. 31. 2008

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]